Tumor Infiltrating Lymphocytes (TIL)

BIOLOGICAL19 trials

Conditions

Advanced Breast CancerAdvanced Solid TumorsBiliary Tract CancerBiliary Tract NeoplasmsBrain CancerBrain MetastasesBrain TumorBreast Cancer

Early Phase 1

Study of GC101 TIL in Brain Glioma (Soochow2)

RecruitingNCT04943913

Shanghai Juncell TherapeuticsGlioma

Start: 2021-05-06End: 2027-05-31Target: 50Updated: 2025-12-11

A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)

RecruitingNCT04960072

Shanghai Juncell TherapeuticsGastrointestinal Tumor

Start: 2021-06-30End: 2026-07-30Target: 50Updated: 2025-12-23

A Study of GC101 TIL in Advanced Solid Tumors (TR)

RecruitingNCT04967833

Shanghai Juncell TherapeuticsAdvanced Solid Tumors

Start: 2021-04-22End: 2026-04-22Target: 20Updated: 2025-12-11

A Study of GC101 TIL in Advanced Breast Cancer (10hospital)

RecruitingNCT05142475

Shanghai Juncell TherapeuticsAdvanced Breast Cancer, Breast Cancer, Effects of Immunotherapy +1

Start: 2021-11-19End: 2027-12-20Target: 50Updated: 2025-12-11

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

NCT05333588

Hebei Senlang Biotechnology Inc., Ltd.Glioblastoma Multiforme, Adult

Start: 2022-02-15End: 2025-02-15Target: 20Updated: 2022-04-19

Phase 1

Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer

NCT04072263

Leiden University Medical CenterOvarian Cancer Recurrent

Start: 2018-08-01End: 2021-12-01Target: 12Updated: 2021-04-01

Study on TIL for the Treatment of r/r Gynecologic Tumors

RecruitingNCT04766320

Shanghai 10th People's HospitalGynecologic Cancer

Start: 2021-01-04End: 2025-01-31Target: 15Updated: 2024-03-06

Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer

RecruitingNCT06530303

Essen BiotechColon Cancer, Colorectal Cancer, Rectum Cancer

Start: 2024-09-29End: 2026-12-28Target: 85Updated: 2024-11-05

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

RecruitingNCT06532812

Essen BiotechBreast Cancer, Breast Cancer Metastatic, Breast Cancer Triple Negative +1

Start: 2024-08-22End: 2026-12-28Target: 85Updated: 2024-11-12

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

RecruitingNCT06532799

Essen BiotechEsophageal Cancer, Esophageal Cancer Metastatic to Bone, Esophageal Cancer Metastatic to Liver +4

Start: 2024-09-10End: 2026-12-28Target: 75Updated: 2024-11-12

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

RecruitingNCT06538012

Essen BiotechLung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell +1

Start: 2024-08-20End: 2026-12-28Target: 85Updated: 2024-10-15

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

RecruitingNCT06640582

Essen BiotechBrain Cancer, Brain Metastases, Brain Tumor +4

Start: 2024-10-20End: 2026-12-28Target: 85Updated: 2024-11-05

Phase 2

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

TerminatedNCT00863330

Wake Forest University Health SciencesMelanoma (Skin)

Start: 2009-02-28End: 2012-07-31Updated: 2024-10-03

A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas

TerminatedNCT02375984

Saint John's Cancer InstituteMetastatic Melanoma

Start: 2016-03-16End: 2017-06-01Updated: 2021-09-22

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

RecruitingNCT03467516

Udai KammulaMelanoma, Uveal, Uveal Neoplasms

Start: 2018-05-14End: 2027-12-31Target: 47Updated: 2025-07-10

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

RecruitingNCT03801083

Udai KammulaBiliary Tract Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma

Start: 2019-02-19End: 2031-01-31Target: 59Updated: 2025-07-10

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

RecruitingNCT03935893

Udai KammulaColorectal Cancer, Gastric Cancer, Merkel Cell Carcinoma +7

Start: 2019-12-03End: 2038-06-30Target: 240Updated: 2025-07-10

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

NCT04383067

Sheba Medical CenterMetastatic Urothelial Carcinoma

Start: 2020-05-12End: 2023-06-01Target: 20Updated: 2021-02-11

Unknown Phase

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

CompletedNCT01701674

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Melanoma

Start: 2012-10-09End: 2025-08-21Updated: 2025-12-19

Blood2025-11-03

CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

Journal for ImmunoTherapy of Cancer2025-04-016 citations

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer.

2024-05-206 citations

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer

Journal for ImmunoTherapy of Cancer2023-11-0124 citations

PO008/#393 Timed adoptive T-cell therapy during chemotherapy in platinum sensitive recurrent epithelial ovarian cancer, the ovacure phase I/II trial

2023-11-01

Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen

Journal for ImmunoTherapy of Cancer2022-02-0112 citations

356 Personalized immunotherapy by adoptive T cell transfer during chemotherapy with or without interferon-alpha in patients with recurrent platinum-sensitive epithelial ovarian cancer

Regular and Young Investigator Award Abstracts2021-11-01

385 Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL)

Regular and Young Investigator Award Abstracts2021-11-01

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Journal for ImmunoTherapy of Cancer2021-10-0161 citations

Uveal Melanoma

Oncology Times2021-02-271 citations

Final report of a pilot trial combining ipilimumab and adoptive cell therapy.

Journal of Clinical Oncology2017-03-012 citations